BRPI0607577A2 - antagonistas cgrp, processo para sua preparação bem como seu uso como medicamento - Google Patents
antagonistas cgrp, processo para sua preparação bem como seu uso como medicamentoInfo
- Publication number
- BRPI0607577A2 BRPI0607577A2 BRPI0607577-0A BRPI0607577A BRPI0607577A2 BR PI0607577 A2 BRPI0607577 A2 BR PI0607577A2 BR PI0607577 A BRPI0607577 A BR PI0607577A BR PI0607577 A2 BRPI0607577 A2 BR PI0607577A2
- Authority
- BR
- Brazil
- Prior art keywords
- preparation
- well
- cgrp antagonists
- salts
- medicine
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Addiction (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Otolaryngology (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
ANTAGONISTAS CGRP, PROCESSO PARA SUA PREPARAçãO BEM COMO SEU USO COMO MEDICAMENTO. A presente invenção refere-se a antagonistas CGRP da fórmula geral I em que R^ 1^, R^ 2^, R^ 3^, R^ 4^ e X são definidos como na reivindicação 1, seus tautómeros, seus isómeros, seus diastereómeros, seus enantiómeros, seus hidratos, suas misturas e seus sais bem como os hidratos dos sais, particularmente seus sais fisiologicamente compatíveis com ácidos ou bases orgánicos ou inorgânicos, bem como aqueles compostos da fórmula geral 1, nos quais um ou mais átomos de hidrogênio são trocados por deutério, medicamentos contendo estes compostos, seu uso e processo para sua preparação.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/EP2005/003094 WO2005092880A1 (de) | 2004-03-29 | 2005-03-23 | Ausgewählte cgrp-antagonisten, verfahren zu deren herstellung sowie deren verwendung als arzneimittel |
PCT/EP2005/004104 WO2005103037A2 (de) | 2004-04-22 | 2005-04-18 | Ausgewählte cgrp-antagonisten, verfahren zu deren herstellung sowie deren verwendung als arzneimittel |
EP05021283A EP1770091A1 (de) | 2005-09-29 | 2005-09-29 | CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel |
PCT/EP2006/002515 WO2006100009A1 (de) | 2005-03-23 | 2006-03-18 | Cgrp-antagonisten, verfahren zu deren herstellung sowie deren verwendung als arzneimittel |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0607577A2 true BRPI0607577A2 (pt) | 2009-09-15 |
Family
ID=36091321
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0607577-0A BRPI0607577A2 (pt) | 2005-03-23 | 2006-03-18 | antagonistas cgrp, processo para sua preparação bem como seu uso como medicamento |
Country Status (10)
Country | Link |
---|---|
US (3) | US7528129B2 (pt) |
EP (2) | EP1770091A1 (pt) |
JP (1) | JP2008538209A (pt) |
KR (1) | KR20070114831A (pt) |
AU (1) | AU2006226615A1 (pt) |
BR (1) | BRPI0607577A2 (pt) |
CA (1) | CA2600909A1 (pt) |
IL (1) | IL186090A0 (pt) |
MX (1) | MX2007011527A (pt) |
WO (1) | WO2006100009A1 (pt) |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10250082A1 (de) * | 2002-10-25 | 2004-05-13 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel |
US7595312B2 (en) | 2002-10-25 | 2009-09-29 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions |
DE102004015723A1 (de) | 2004-03-29 | 2005-10-20 | Boehringer Ingelheim Pharma | Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel |
US7279471B2 (en) * | 2004-04-15 | 2007-10-09 | Boehringer Ingelheim International Gmbh | Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions |
US7696195B2 (en) | 2004-04-22 | 2010-04-13 | Boehringer Ingelheim International Gmbh | Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions |
US7491717B2 (en) * | 2005-03-23 | 2009-02-17 | Boehringer Ingelheim International Gmbh | Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions |
DE102005038831A1 (de) * | 2005-08-17 | 2007-02-22 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel |
EP1770086A1 (de) * | 2005-09-29 | 2007-04-04 | Boehringer Ingelheim Pharma GmbH & Co. KG | Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel |
DE102005050892A1 (de) * | 2005-10-21 | 2007-04-26 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel |
SI2380592T1 (en) | 2005-11-14 | 2018-06-29 | Teva Pharmaceuticals International Gmbh | The antibody to the calcitonin-related peptide antagonist |
MX2008015562A (es) * | 2006-06-08 | 2008-12-17 | Boehringer Ingelheim Int | Tratamiento de trastornos gastrointestinales con antagonistas de cgrp. |
DE102007038251A1 (de) | 2007-08-13 | 2009-02-19 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neues Herstellverfahren |
DE102007038250A1 (de) * | 2007-08-13 | 2009-02-19 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neues Herstellverfahren |
MX2010003849A (es) | 2007-10-18 | 2010-04-27 | Boehringer Ingelheim Int | Antagonistas de cgrp. |
EP2065381A1 (de) * | 2007-10-18 | 2009-06-03 | Boehringer Ingelheim Pharma GmbH & Co. KG | CGRP Antagonisten |
EP2065382A1 (de) * | 2007-10-18 | 2009-06-03 | Boehringer Ingelheim Pharma GmbH & Co. KG | CGRP Antagonisten |
EP2225223B1 (de) | 2007-11-22 | 2017-01-11 | Boehringer Ingelheim International GmbH | Organische verbindungen |
IE20070928A1 (en) * | 2007-12-21 | 2009-09-30 | Giuliani Int Ltd | Multi target ligands |
CN101959528A (zh) * | 2008-03-04 | 2011-01-26 | 辉瑞有限公司 | 治疗慢性疼痛的方法 |
JP5745861B2 (ja) | 2008-03-04 | 2015-07-08 | ファイザー・リミテッドPfizer Limited | 炎症性疼痛を治療する方法 |
EP3165236B1 (en) | 2009-08-28 | 2022-03-16 | Teva Pharmaceuticals International GmbH | Methods for treating visceral pain by administering antagonist antibodies directed against calcitonin gene-related peptide |
EP2627329B1 (en) * | 2010-10-12 | 2015-07-08 | AstraZeneca AB | Trpa1 receptor antagonist |
HUE044062T2 (hu) | 2011-05-20 | 2019-09-30 | Alderbio Holdings Llc | Anti-CGRP készítmények és alkalmazásuk |
BR112013029959A8 (pt) | 2011-05-20 | 2021-09-08 | Alderbio Holdings Llc | Anticorpos anti-cgrp e anti-cgrpr e seu uso para prevenir ou inibir fotofobia ou aversão à luz, composição farmacêutica compreendendo os referidos anticorpos, bem como sequência de ácido nucleico e célula recombinante |
AU2012258976B8 (en) | 2011-05-20 | 2017-07-20 | H. Lundbeck A/S | Use of anti-CGRP or anti-CGRP-R antibodies or antibody fragments to treat or prevent chronic and acute forms of diarrhea |
PE20220337A1 (es) | 2014-03-21 | 2022-03-14 | Teva Pharmaceuticals Int Gmbh | Anticuerpos antagonistas dirigidos contra el peptido relacionado con el gen de calcitonina y metodos que usan los mismos |
US10556945B2 (en) | 2014-03-21 | 2020-02-11 | Teva Pharmaceuticals International Gmbh | Antagonist antibodies directed against calcitonin gene-related peptide and methods using same |
CN104977383A (zh) * | 2015-06-18 | 2015-10-14 | 中山鼎晟生物科技有限公司 | 一种螺旋藻类食品中微囊毒素的快速定量检测方法 |
GB201519195D0 (en) | 2015-10-30 | 2015-12-16 | Heptares Therapeutics Ltd | CGRP Receptor Antagonists |
GB201519194D0 (en) | 2015-10-30 | 2015-12-16 | Heptares Therapeutics Ltd | CGRP receptor antagonists |
GB201519196D0 (en) | 2015-10-30 | 2015-12-16 | Heptares Therapeutics Ltd | CGRP Receptor Antagonists |
KR20220031944A (ko) | 2016-09-23 | 2022-03-14 | 테바 파마슈티컬스 인터내셔널 게엠베하 | 불응성 편두통의 치료 |
SG11202106766SA (en) | 2019-01-08 | 2021-07-29 | H Lundbeck As | Acute treatment and rapid treatment of headache using anti-cgrp antibodies |
CN112174971A (zh) * | 2020-10-27 | 2021-01-05 | 仙桃吉星新材料股份有限公司 | 一种四氟硼酸螺环季铵盐的提纯方法 |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US634449A (en) * | 1898-12-31 | 1899-10-10 | Peter Joseph Foulon | Apparatus for forming gelatin tubes. |
JPH07108484B2 (ja) * | 1990-11-30 | 1995-11-22 | 大阪ダイヤモンド工業株式会社 | 歯車研削用砥石並びに歯車加工法 |
EE04375B1 (et) | 1996-09-10 | 2004-10-15 | Dr. Karl Thomae Gmbh | Modifitseeritud aminohapped, neid ühendeid sisaldavad ravimid ja nende valmistamise meetod |
US20030069231A1 (en) | 1999-10-12 | 2003-04-10 | Klaus Rudolf | Modified aminoacids, pharmaceuticals containing these compounds and method for their production |
EP1117662A1 (en) | 1998-09-30 | 2001-07-25 | Merck Sharp & Dohme Limited | Benzimidazolinyl piperidines as cgrp ligands |
DE19937304C2 (de) | 1999-08-10 | 2003-08-21 | Boehringer Ingelheim Pharma | Verwendung von CGRP-Antagonisten zur Bekämpfung menopausaler Hitzewallungen |
US6521609B1 (en) | 1999-08-10 | 2003-02-18 | Boehringer Ingelheim Pharma Kg | Use of CGRP antagonists and CGRP release inhibitors for combating menopausal hot flushes |
DE19963868A1 (de) * | 1999-12-30 | 2001-07-12 | Boehringer Ingelheim Pharma | Neue substituierte Piperidine, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
AU2003237255B8 (en) * | 2002-06-05 | 2010-01-07 | Bristol-Myers Squibb Company | Calcitonin gene related peptide receptor antagonists |
DE10250082A1 (de) | 2002-10-25 | 2004-05-13 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel |
US7595312B2 (en) | 2002-10-25 | 2009-09-29 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions |
DE10250080A1 (de) * | 2002-10-25 | 2004-05-13 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel |
DE10300973A1 (de) | 2003-01-14 | 2004-07-22 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Carbonsäuren und deren Ester, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
DE102004015723A1 (de) * | 2004-03-29 | 2005-10-20 | Boehringer Ingelheim Pharma | Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel |
TW200533398A (en) | 2004-03-29 | 2005-10-16 | Bristol Myers Squibb Co | Novel therapeutic agents for the treatment of migraine |
DE102004019492A1 (de) * | 2004-04-22 | 2005-11-10 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel |
-
2005
- 2005-09-29 EP EP05021283A patent/EP1770091A1/de not_active Withdrawn
-
2006
- 2006-03-18 BR BRPI0607577-0A patent/BRPI0607577A2/pt not_active IP Right Cessation
- 2006-03-18 CA CA002600909A patent/CA2600909A1/en not_active Abandoned
- 2006-03-18 EP EP06723538A patent/EP1863799A1/de not_active Withdrawn
- 2006-03-18 MX MX2007011527A patent/MX2007011527A/es unknown
- 2006-03-18 AU AU2006226615A patent/AU2006226615A1/en not_active Abandoned
- 2006-03-18 KR KR1020077024324A patent/KR20070114831A/ko not_active Application Discontinuation
- 2006-03-18 WO PCT/EP2006/002515 patent/WO2006100009A1/de active Application Filing
- 2006-03-18 JP JP2008502299A patent/JP2008538209A/ja active Pending
- 2006-03-22 US US11/277,177 patent/US7528129B2/en active Active
-
2007
- 2007-09-20 IL IL186090A patent/IL186090A0/en unknown
-
2009
- 2009-01-30 US US12/363,175 patent/US7696209B2/en active Active
-
2010
- 2010-02-18 US US12/707,890 patent/US20100144716A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP1863799A1 (de) | 2007-12-12 |
AU2006226615A1 (en) | 2006-09-28 |
WO2006100009A1 (de) | 2006-09-28 |
CA2600909A1 (en) | 2006-09-28 |
US20090186881A1 (en) | 2009-07-23 |
US7696209B2 (en) | 2010-04-13 |
JP2008538209A (ja) | 2008-10-16 |
EP1770091A1 (de) | 2007-04-04 |
IL186090A0 (en) | 2008-01-20 |
US20100144716A1 (en) | 2010-06-10 |
US7528129B2 (en) | 2009-05-05 |
KR20070114831A (ko) | 2007-12-04 |
US20060252931A1 (en) | 2006-11-09 |
MX2007011527A (es) | 2007-10-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0607577A2 (pt) | antagonistas cgrp, processo para sua preparação bem como seu uso como medicamento | |
BR0315642A (pt) | Antagonistas de cgrp selecionados, processo para sua preparação, bem como seu uso como medicamento | |
BRPI0614831A2 (pt) | antagonistas de cgrp selecionados, processo para sua produção bem como seu uso como medicamentos | |
BRPI0718813B8 (pt) | compostos derivados de 1,1-dióxido de 1,4-benzotiepina, medicamento que os compreendem e seus usos | |
BR0315665A (pt) | Antagonistas de cgrp selecionados, processos para preparação dos mesmos, bem como uso dos mesmos como medicamento | |
BRPI0513086A (pt) | 8-pirrolidinoxantinas bicìclicas substituìdas, processo para a produção das mesmas e seu uso como medicamentos | |
BRPI0609719B8 (pt) | derivados de acetilenil-pirazol-pirimidina como antagonistas de mgbur2 | |
BRPI0509368A (pt) | antagonistas cgrp selecionados, processo para a sua fabricação bem como seu uso como medicamento | |
BR0317283A (pt) | Derivados heterocìclicos de flúor-glicosìdeo, medicamentos contendo estes compostos e seu uso | |
BRPI0508830A (pt) | derivados de benzeno substituìdos por glucopiranosila, medicamentos contendo esses compostos, seu uso e processo para sua fabricação | |
BRPI0612580A8 (pt) | glicinamidas substituídas, processo para a sua preparação e uso da mesma como medicamentos | |
BRPI0510770A (pt) | derivados de fluorglicosìdeos de pirazóis, medicamentos contendo esses compostos e seu uso | |
BRPI0514091A (pt) | 8-aminoalquiltioxantinas substituìdas, e seu uso como inibidores de dipepetidil peptidase iv | |
BRPI0713367A2 (pt) | composto, composição farmacêutica, uso de um composto, e, método de tratamento de um distúrbio de agregação de plaqueta | |
BRPI0415683A (pt) | inibidores da reabsorção de norepinefrina para o tratamento de distúrbios do sistema nervoso central | |
BRPI0411713B8 (pt) | compostos, processo para a sua manufatura, composições farmacêuticas que compreendem os mesmos, método para tratamento e/ou profilaxia de enfermidades que estão associadas com dpp-iv e sua utilização | |
BR0316605A (pt) | Derivados de fluorglicosìdeos aromáticos, medicamentos contendo estes compostos e sua aplicação | |
BR0211284A (pt) | Derivados de 1-fenilsulfonil-1,3-dihidro-2h-indol-2-ona, a respectiva preparação e a respectiva aplicação em terapêutica | |
BR0312513A (pt) | Derivados de glicosìdeo de tiofeno, processos para a produção dos mesmos, medicamentos que contêm esses compostos e uso dos mesmos | |
BR112015020242A2 (pt) | sulfamoil-arilamidas e seu uso como medicamentos para o tratamento da hepatite b | |
BR0213539A (pt) | Compostos, processo para a preparação de compostos, composições farmacêuticas que compreendem um composto método para o tratamento e/ou profilaxia de enfermidades que estão associadas com dpp iv e utilização desses compostos | |
BRPI0507309A (pt) | derivados de ácido 7-fenilamino-4quinolon-3-carboxìlico, processos para produção e seu uso como medicamento | |
BRPI0512335A (pt) | compostos, processo para a sua manufatura, composições farmacêuticas que os compreendem, método para o tratamento e/ou prevenção de enfermidades e sua utilização | |
BRPI0516842A (pt) | compostos, processo para a sua manufatura, composições farmacêuticas que os compreendem, método para o tratamento terapêutico e/ou profilático de enfermidades que são moduladas por lxr alfa e/ou lxr beta agonistas e uso desses compostos | |
BRPI0717367B8 (pt) | di-hidropirazolonas substituídas, seus usos e seu processo de preparação, e medicamento |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 5A E 6A ANUIDADES. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2161 DE 05/06/2012. |